alirocumab

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels
New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels
24/7 Wall St
FDA
advisory panels
Regeneron
AbbVie
Amgen
Repatha
alirocumab
PCSK9 inhibitors
Flag link:
FDA staff: Sanofi/Regeneron drug lowers LDL; is well tolerated
FDA staff: Sanofi/Regeneron drug lowers LDL; is well tolerated
Yahoo/Reuters
FDA
Sanofi
Regeneron
alirocumab
advisory panels
Flag link:
More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes
More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes
Forbes
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
alirocumab
evolocumab
Flag link:
Amgen, Regeneron Stocks Go Up as Drugs Bring Cholesterol Down
Amgen, Regeneron Stocks Go Up as Drugs Bring Cholesterol Down
Forbes
Amgen
Regeneron
PCSK9 inhibitors
alirocumab
evolocumab
Flag link:
New Cholesterol Drugs: Highly Effective But Important Questions Remain
New Cholesterol Drugs: Highly Effective But Important Questions Remain
Forbes
PCSK9 inhibitors
alirocumab
evolocumab
Amgen
Sanofi
Regeneron
Flag link:
Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race
Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race
Bloomberg
Sanofi
Regeneron
Amgen
alirocumab
evolocumab
PCSK9 inhibitors
Flag link:
FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
Sanofi, Regeneron cholesterol drug also effective in monthly doses
Sanofi, Regeneron cholesterol drug also effective in monthly doses
Yahoo/Reuters
Sanofi
Regeneron
alirocumab
Flag link:
5 Potential Blockbuster Drugs Set To Launch In 2015
5 Potential Blockbuster Drugs Set To Launch In 2015
Investors.com
Amgen
Regeneron
evolocumab
alirocumab
Alexion
asfotase alfa
Novartis
LCZ696
Pfizer
palbociclib
Flag link:
Regeneron drug highly effective for those who can't take statins: study
Regeneron drug highly effective for those who can't take statins: study
Reuters
Regeneron
statins
Sanofi
alirocumab
Flag link:
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Yahoo
Amgen
Sanofi
Regeneron
patents
alirocumab
monoclonal antibodies
evolocumab
Flag link:
Regeneron touts its allergy drug as a blockbuster in waiting
Regeneron touts its allergy drug as a blockbuster in waiting
Fierce Biotech
Regeneron
allergy
alirocumab
dupilumab
Flag link:
Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Yahoo/PR Newswire
Sanofi
Regeneron
alirocumab
hypercholesterolemia
Flag link:
As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?
As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?
First Word Pharma
cardiologists
physicians
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
evolocumab
alirocumab
Flag link:
Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials
Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials
Yahoo/Reuters
cholesterol
Sanofi
Regeneron
alirocumab
Flag link:
New Cholesterol Fighters To Take Center Stage At ACC
New Cholesterol Fighters To Take Center Stage At ACC
Investors.com
cholesterol
Pfizer
Amgen
Regeneron
Sanofi
PCSK9 inhibitors
American Cardiology Conference
alirocumab
Flag link:
FDA Concerns Are the Least of These Drugs' Worries
FDA Concerns Are the Least of These Drugs' Worries
Motley Fool
FDA
PCSK9 inhibitors
Regeneron
Sanofi
Merck
alirocumab
Flag link:
FDA asks Sanofi, Regeneron to assess cholesterol drug's cognitive risks
FDA asks Sanofi, Regeneron to assess cholesterol drug's cognitive risks
Yahoo/Reuters
Sanofi
FDA
Regeneron
alirocumab
PCSK9 inhibitors
Flag link:
Sanofi to tap ACC registry for cardiovascular clinical trial
Sanofi to tap ACC registry for cardiovascular clinical trial
Yahoo/Reuters
Sanofi
clinical trials
alirocumab
American College of Cardiology
Flag link:
3 New Cholesterol Treatments Worth Watching
3 New Cholesterol Treatments Worth Watching
Motley Fool
Sanofi
Regeneron
Amgen
alirocumab
AMG 145
RN-316
Pfizer
Flag link:

Pages